期刊
CURRENT OPINION IN RHEUMATOLOGY
卷 33, 期 2, 页码 181-189出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0000000000000772
关键词
biological therapies; systemic lupus erythematosus; therapy; treatment update
类别
资金
- NIH
This review provides an overview of recent clinical trials in systemic lupus erythematosus (SLE), focusing on the use of monoclonal antibodies, costimulatory molecule blockers, kinase inhibitors, and cytokine replenishment. Therapeutic options for SLE patients are expanding, highlighting the importance of precision medicine based on pathogenetic mechanisms.
Purpose of review This review gives an overview of the recently published clinical trials in systemic lupus erythematosus (SLE). Recent findings Our continuously improving understanding of the cellular and molecular mechanisms, which are involved in the pathogenesis of SLE, has inspired the performance of multiple clinical trials in an attempt to modify recognized targets. Here, we summarize results obtained from recent trials, which used monoclonal antibodies blocking cytokines, blockers of costimulatory molecules or deleting immune cells, small drug inhibitors of kinases and replenishment of cytokines. The therapeutic options for patients with SLE grow continuously and in parallel it raises the need for pathogenetic mechanism-based precision medicine so that we may select the right treatment for the right patient.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据